References
1. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones: T.M. Willson, et al.; J. Med. Chem. 39: 665 (1996). 2. Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]- thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent: T. Fujita, et al.; Diabetes 32: 804 (1983). 3. [[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents:B.C. Cantello, et al.; J. Med. Chem. 37: 3977 (1994). 4. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo: X. Xin, et al.; J. Biol. Chem. 274: 9116 (1999). 5. The thiazolidinedione ciglitazone reduces bacterial outgrowth and early inflammation during Streptococcus pneumoniae pneumonia in mice: M.E. Stegenga, et al.; Crit. Care Med. 37: 614 (2009). 6. Ciglitazone, a novel inhibitor of lung apoptosis following hemorrhagic shock: R.S. Chima, et al.; Int. J. Clin. Exp. Med. 3: 1 (2010)USBio References
No references available
TDS
NCBI
UniProt
Tech Support
Customer Service
